Provenge
FDA Expands Zytiga for Late-Stage Prostate Cancer »
"The U.S. Food and Drug Administration today expanded the approved use of Zytiga (abiraterone acetate) to treat men with late-stage (metastatic) castration-resistant prostate cancer prior to receiving chemotherapy.
The FDA initially appr"...
Read the FDA Expands Zytiga for Late-Stage Prostate Cancer article »
Provenge
OVERDOSE
Each PROVENGE infusion comprises the maximum number of cells that can be manufactured from a single leukapheresis procedure. The number of cells in PROVENGE does not exceed the number of cells collected from the leukapheresis. There are no known instances of overdosage from either a single infusion or a full course of therapy with PROVENGE.
CONTRAINDICATIONS
None.
Last reviewed on RxList: 7/18/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Provenge Information
Provenge - User Reviews
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Cancer
Get the latest treatment options.






